NEW YORK— Biomarker test developer Biovica has filed a 501(k) submission with the US Food and Drug Administration for its DiviTum assay for monitoring breast cancer treatment response.
To read the full story....
...and receive Weekly News bulletins.
Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.
Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.